[
  {
    "ts": null,
    "headline": "Apple Stock’s Resilience Means This Is an Opportunity, Says BofA. Plus, Meta, Occidental, and More.",
    "summary": "RESEARCH REPORTS These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or recommendations of Barron’s.",
    "url": "https://finnhub.io/api/news?id=6a12d218178a2619bcb1b7f8bc3dd3a2cbc0968886249d317d9c13ad3f36dd18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744414140,
      "headline": "Apple Stock’s Resilience Means This Is an Opportunity, Says BofA. Plus, Meta, Occidental, and More.",
      "id": 133895795,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "RESEARCH REPORTS These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the views or recommendations of Barron’s.",
      "url": "https://finnhub.io/api/news?id=6a12d218178a2619bcb1b7f8bc3dd3a2cbc0968886249d317d9c13ad3f36dd18"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly and Company (LLY) Is the Best Medical Stock to Buy According to Billionaires",
    "summary": "We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and […]",
    "url": "https://finnhub.io/api/news?id=6b622881b626d2cf8e2759e6c996454a05b3c2fe902bf2f42663f7e405376943",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744402272,
      "headline": "Why Eli Lilly and Company (LLY) Is the Best Medical Stock to Buy According to Billionaires",
      "id": 133895924,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best medical stocks to buy according to billionaires. Why are Healthcare Stocks Under Pressure? Some experts view medical, healthcare, and […]",
      "url": "https://finnhub.io/api/news?id=6b622881b626d2cf8e2759e6c996454a05b3c2fe902bf2f42663f7e405376943"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Tries to Kill Custom Tirzepatide--But This Healthtech Rebel Isn't Backing Down",
    "summary": "OrderlyMeds fights back after Big Pharma crackdown, igniting a battle over the future of personalized medicine",
    "url": "https://finnhub.io/api/news?id=5713fbf75773c4c387dfdbc9498b16351904788d80d40f4df8a06c881a0b962a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744394182,
      "headline": "Eli Lilly Tries to Kill Custom Tirzepatide--But This Healthtech Rebel Isn't Backing Down",
      "id": 133880587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "OrderlyMeds fights back after Big Pharma crackdown, igniting a battle over the future of personalized medicine",
      "url": "https://finnhub.io/api/news?id=5713fbf75773c4c387dfdbc9498b16351904788d80d40f4df8a06c881a0b962a"
    }
  },
  {
    "ts": null,
    "headline": "Novartis commits $23bn to US manufacturing amid tariff threats",
    "summary": "Novartis plans new manufacturing sites and a second R&D hub as it shifts key operations to the US.",
    "url": "https://finnhub.io/api/news?id=ea717315faf0ea2430cc83ca0a8aebba991b94d40a1c49fdae12e9e4347feb57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744390546,
      "headline": "Novartis commits $23bn to US manufacturing amid tariff threats",
      "id": 133880588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novartis plans new manufacturing sites and a second R&D hub as it shifts key operations to the US.",
      "url": "https://finnhub.io/api/news?id=ea717315faf0ea2430cc83ca0a8aebba991b94d40a1c49fdae12e9e4347feb57"
    }
  },
  {
    "ts": null,
    "headline": "Novo Remade Denmark. Then Came the Stock Selloff.",
    "summary": "Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from science to geopolitics.",
    "url": "https://finnhub.io/api/news?id=b524bf092d51ca0f3caf4eddd60b486b636d205d4f5bd49a06031cc845e968c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744388580,
      "headline": "Novo Remade Denmark. Then Came the Stock Selloff.",
      "id": 133880589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity now is under attack on multiple fronts, from science to geopolitics.",
      "url": "https://finnhub.io/api/news?id=b524bf092d51ca0f3caf4eddd60b486b636d205d4f5bd49a06031cc845e968c6"
    }
  },
  {
    "ts": null,
    "headline": "FASB sets clock for derivatives rules update",
    "summary": "Existing accounting standards have led to “scope creep,” with derivative standards being applied too often, FASB Chair Richard Jones said.",
    "url": "https://finnhub.io/api/news?id=69330b9475880aba7ca49dcee12944e4c2cf0a238d89bd4a4da24547bb715fc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744387048,
      "headline": "FASB sets clock for derivatives rules update",
      "id": 133895925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Existing accounting standards have led to “scope creep,” with derivative standards being applied too often, FASB Chair Richard Jones said.",
      "url": "https://finnhub.io/api/news?id=69330b9475880aba7ca49dcee12944e4c2cf0a238d89bd4a4da24547bb715fc3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Challenges Custom Tirzepatide--But This Healthtech Startup Is Fighting Back",
    "summary": "Analysts stay bullish despite a massive earnings hit--here's why investors aren't running for the exits.",
    "url": "https://finnhub.io/api/news?id=d820ec06e05218ebd217ff389f746e12cc456e35ed4842f3162e627b70bf37e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744385910,
      "headline": "Eli Lilly Challenges Custom Tirzepatide--But This Healthtech Startup Is Fighting Back",
      "id": 133880590,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Analysts stay bullish despite a massive earnings hit--here's why investors aren't running for the exits.",
      "url": "https://finnhub.io/api/news?id=d820ec06e05218ebd217ff389f746e12cc456e35ed4842f3162e627b70bf37e6"
    }
  },
  {
    "ts": null,
    "headline": "Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche",
    "summary": "The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.",
    "url": "https://finnhub.io/api/news?id=33bdcc0fa85926f5ec1fdae035e6d3dd277c939d027c8a08a7be580dcc5a1860",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744381620,
      "headline": "Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche",
      "id": 133880591,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Danish biotech’s recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.",
      "url": "https://finnhub.io/api/news?id=33bdcc0fa85926f5ec1fdae035e6d3dd277c939d027c8a08a7be580dcc5a1860"
    }
  },
  {
    "ts": null,
    "headline": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
    "summary": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
    "url": "https://finnhub.io/api/news?id=214fd3e776f4c24239b520e6243dfefd64cb5211ed2c7b16f5e4c4f6a4179d56",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744377180,
      "headline": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
      "id": 133885776,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
      "url": "https://finnhub.io/api/news?id=214fd3e776f4c24239b520e6243dfefd64cb5211ed2c7b16f5e4c4f6a4179d56"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Pulls Back on the Weight-Loss Drug Hype",
    "summary": "Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who track healthcare stocks on Wall Street: that the market for the new, effective obesity drugs will be even bigger than anyone expects.  Shares of  Eli Lilly  have trailed the market, and Novo’s American depositary receipt is down roughly half over the past year, but analysts kept raising their estimates for sales of both company’s top weight-loss drugs.  Why were the stocks underperforming if the growth outlook kept getting better?",
    "url": "https://finnhub.io/api/news?id=87ec9680272a417e6ad912edbec7891945f65ec82a497e80253579908523f6c6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744376760,
      "headline": "Wall Street Pulls Back on the Weight-Loss Drug Hype",
      "id": 133880592,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Through all the market madness of the past two years, there has been one truth universally acknowledged by the analysts who track healthcare stocks on Wall Street: that the market for the new, effective obesity drugs will be even bigger than anyone expects.  Shares of  Eli Lilly  have trailed the market, and Novo’s American depositary receipt is down roughly half over the past year, but analysts kept raising their estimates for sales of both company’s top weight-loss drugs.  Why were the stocks underperforming if the growth outlook kept getting better?",
      "url": "https://finnhub.io/api/news?id=87ec9680272a417e6ad912edbec7891945f65ec82a497e80253579908523f6c6"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri",
    "summary": "Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=f6688fadf5c545ffaedd1ba824ee4e6043a0cb3690ec555327e70aacb2833d01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744368780,
      "headline": "The Zacks Analyst Blog Highlights Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri",
      "id": 133880593,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, American Express, Thermo Fisher, Steel Partners and Oil-Dri are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=f6688fadf5c545ffaedd1ba824ee4e6043a0cb3690ec555327e70aacb2833d01"
    }
  },
  {
    "ts": null,
    "headline": "How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs",
    "summary": "Political pressure and persistently high interest rates have some wondering if the industry’s model is broken.",
    "url": "https://finnhub.io/api/news?id=615fa5fb1fde395965789cf5bcbb46c550f538474005476abd9800675c2ae740",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744363800,
      "headline": "How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs",
      "id": 133880594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Political pressure and persistently high interest rates have some wondering if the industry’s model is broken.",
      "url": "https://finnhub.io/api/news?id=615fa5fb1fde395965789cf5bcbb46c550f538474005476abd9800675c2ae740"
    }
  },
  {
    "ts": null,
    "headline": "Pharma’s US manufacturing moment: Where companies are making the biggest moves",
    "summary": "The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.",
    "url": "https://finnhub.io/api/news?id=d17e0a6b405718246d3091f4b7ddba60090760d1e24f1b6cd1bb038889f5e884",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744355602,
      "headline": "Pharma’s US manufacturing moment: Where companies are making the biggest moves",
      "id": 133880595,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.",
      "url": "https://finnhub.io/api/news?id=d17e0a6b405718246d3091f4b7ddba60090760d1e24f1b6cd1bb038889f5e884"
    }
  },
  {
    "ts": null,
    "headline": "Harbor International Compounders Fund Q4 2024 Commentary",
    "summary": "The Harbor International Compounders Fund returned -9.59% compared to the MSCI All Country World ex-US Index, which returned -7.60%.",
    "url": "https://finnhub.io/api/news?id=38b432cd36cb4a6b4e4fec2425ba3ff35ac01e6d805a4055c0c2827cc8042b14",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744331400,
      "headline": "Harbor International Compounders Fund Q4 2024 Commentary",
      "id": 133875879,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1327882500/image_1327882500.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Harbor International Compounders Fund returned -9.59% compared to the MSCI All Country World ex-US Index, which returned -7.60%.",
      "url": "https://finnhub.io/api/news?id=38b432cd36cb4a6b4e4fec2425ba3ff35ac01e6d805a4055c0c2827cc8042b14"
    }
  },
  {
    "ts": null,
    "headline": "Harbor International Compounders ETF Q4 2024 Commentary",
    "summary": "The Harbor International Compounders ETF returned -9.22% compared to the MSCI All Country World ex-US Index, which returned -7.60%.",
    "url": "https://finnhub.io/api/news?id=01f05118ffa5731f966c2f9b45c102c1838b2b985a153647a19f184c64bac906",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744331400,
      "headline": "Harbor International Compounders ETF Q4 2024 Commentary",
      "id": 133875878,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1335295270/image_1335295270.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Harbor International Compounders ETF returned -9.22% compared to the MSCI All Country World ex-US Index, which returned -7.60%.",
      "url": "https://finnhub.io/api/news?id=01f05118ffa5731f966c2f9b45c102c1838b2b985a153647a19f184c64bac906"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Health Care ETF Q4 2024 Commentary",
    "summary": "Harbor Health Care ETF Q4 2024 Commentary",
    "url": "https://finnhub.io/api/news?id=be689041956141d37a574c922643369ee8f04ea6184921281e2889361a49eb24",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744331400,
      "headline": "Harbor Health Care ETF Q4 2024 Commentary",
      "id": 133875877,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=be689041956141d37a574c922643369ee8f04ea6184921281e2889361a49eb24"
    }
  }
]